PRESS RELEASE published on 06/13/2025 at 07:30, 7 months 21 days ago Inside Information / Other news releases MaaT Pharma presents updated positive data for Xervyteg® in treating acute Graft-versus-Host Disease at EHA Congress, validating high efficacy observed in pivotal ARES study MaaT Pharma Acute Graft-versus-Host Disease EMA Approval Xervyteg EAP Data
PRESS RELEASE published on 06/13/2025 at 07:30, 7 months 21 days ago Informations privilégiées / Autres communiqués MaaT Pharma présente des données actualisées positives pour Xervyteg® lors du Congrès de l’EHA confirmant une forte efficacité observée dans l’étude pivotale ARES dans la maladie aiguë du greffon contre l’hôte Thérapie MaaT Pharma AGvH Xervyteg EHA
BRIEF published on 05/12/2025 at 07:35, 8 months 23 days ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
BRIEF published on 05/12/2025 at 07:35, 8 months 23 days ago Données prometteuses pour MaaT033 dans la SLA Microbiome Sclérose Latérale Amyotrophique MaaT033 Sécurité Et Tolérabilité Essai Clinique Phase 1b
PRESS RELEASE published on 05/12/2025 at 07:30, 8 months 23 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce des données finales prometteuses pour son essai de Phase 1b évaluant MaaT033 dans la Sclérose Latérale Amyotrophique (SLA). Résultats encourageants et implications thérapeutiques importantes Microbiome Ecosystem Therapies MaaT Pharma Sclérose Latérale Amyotrophique Phase 1b Modulation Du Microbiote
BRIEF published on 04/08/2025 at 07:35, 9 months 26 days ago MaaT Pharma annonce des résultats intermédiaires positifs concernant l'innocuité du MaaT033 MaaT Pharma Essai De Phase 2b MaaT033 Allo-GCSH Sécurité DSM
BRIEF published on 04/08/2025 at 07:35, 9 months 26 days ago MaaT Pharma Announces Positive Interim Safety Results for MaaT033 Phase 2B Trial MaaT Pharma MaaT033 Allo-HSCT DSM Safety
PRESS RELEASE published on 04/08/2025 at 07:30, 9 months 26 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce résultat positif analyse intermédiaire sécurité essai clinique Phase 2b MaaT033 allo-GCSH. DSMB recommande poursuite essai sans modification Sécurité DSMB MaaT Pharma Analyse Intermédiaire Allo-GCSH
PRESS RELEASE published on 04/08/2025 at 07:30, 9 months 26 days ago Inside Information / Other news releases MaaT Pharma announces positive safety interim analysis from DSMB for Phase 2b trial evaluating MaaT033 for patients receiving Allo-HSCT, demonstrating favorable safety profile and tolerability Phase 2B Trial MaaT Pharma Safety Analysis MaaT033 Allo-HSCT
BRIEF published on 04/07/2025 at 07:35, 9 months 27 days ago MaaT Pharma : Nouvelle couverture par H.C. Wainwright & Co Cancer Cotation Euronext Microbiome Ecosystem Therapies MaaT Pharma H.C. Wainwright & Co
Published on 02/04/2026 at 16:15, 6 hours 29 minutes ago Trans Canada Gold Enters into an Option Agreement with Bear Mountain Gold Mines to Acquire a 60% Interest in the Harrison Lake District Scale Gold Property, with $10.0 Million Dollars in Prior Exploration Expenditures
Published on 02/04/2026 at 15:45, 6 hours 59 minutes ago Patriot.Tv's Jd Rucker Explains Billie Eilish's Comments on ICE, Offers ICE Commentary as Exhibit A of Celebrity Sound Bite Politics
Published on 02/04/2026 at 15:00, 7 hours 44 minutes ago Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale
Published on 02/04/2026 at 20:54, 1 hour 50 minutes ago Elmos Semiconductor SE is planning to distribute 36 million Euro to shareholders for the fiscal year 2025
Published on 02/04/2026 at 20:36, 2 hours 8 minutes ago EQS-Adhoc: Elmos Semiconductor SE approves share buyback program via the stock exchange of 10 million Euro and dividend proposal of 1.50 Euro per share for fiscal year 2025
Published on 02/04/2026 at 20:00, 2 hours 44 minutes ago Belgium's Ingmar De Vos elected to Executive Board of International Olympic Committee
Published on 02/04/2026 at 18:55, 3 hours 49 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/04/2026 at 18:40, 4 hours 4 minutes ago Robin Zeng: Unlocking the Sustainable Energy Era with Zero-Carbon Technology
Published on 02/04/2026 at 18:04, 4 hours 40 minutes ago Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 4 hours 40 minutes ago Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 4 hours 59 minutes ago Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 4 hours 59 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
